Frontiers in Clinical Drug Research — HIV: Volume 4
This book is edited by Dr. Atta-ur-Rahman is published on Feb 26th, 2019
Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the book series covers a multidisciplinary range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs used in the treatment of AIDS (including HAART) and resulting complications. The book series also informs readers about the virology and immunological study of HIV. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.
The fourth volume of this series features 5 chapters that cover these topics:
- – Design and Synthesis of HIV-1 Protease Inhibitors
– Potential Magnetic Nanotherapeutics for Management of neuroAIDS
– Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing
– The Development and Clinical Progress on Chemokine Receptor-Based HIV Entry Inhibitors
– Sexually Transmitted Co-infections in Persons Living with HIV
About The Editor:
Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1142 international publications in several fields of organic chemistry including 775 research publications, 43 international patents, 70 chapters in books and 253 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world’s leading encyclopedic series of volumes on natural products “Studies in Natural Product Chemistry” 60 volumes of which have been published under his Editorship by Elsevier during the last two decades.
For further information, please visit:
Faizan ul Haq